57076-71-8

Basic information

• Product Name: DENBUFYLLINE
• Synonyms: 3,7-dihydro-1,3-dibutyl-7-(2-oxopropyl)-1h-purine-2,6-dione;3,7-dihydro-1,3-dibutyl-7-(2-oxopropyl)-1h-purine-6-dione;brl30892;1,3-DI-N-BUTYL-7-(2'-OXOPROPYL)XANTHINE;DENBUFYLLINE;1,3-Dibutyl-3,7-dihydro-7-(2-oxopropyl)-1H-purine-2,6-dione;7-Acetonyl-1,3-dibutyl-3,7-dihydro-1H-purine-2,6-dione
• CAS NO: 57076-71-8
• Molecular Formula: C16H24N4O3
• Molecular Weight: 320.39
• Product Categories: Inhibitors
• Mol File: 57076-71-8.mol
• Article Data: 3

Chemical Properties

• Melting Point: 98-100°C
• Boiling Point: 514.8°Cat760mmHg
• Flash Point: 265.1°C
• Appearance: /
• Density: 1.23g/cm³
• Vapor Pressure: 1.04E-10mmHg at 25°C
• Refractive Index: 1.594
• Storage Temp.: Refrigerator
• Solubility: DMSO, Methanol
• CAS DataBase Reference: DENBUFYLLINE(CAS DataBase Reference)
• NIST Chemistry Reference: DENBUFYLLINE(57076-71-8)
• EPA Substance Registry System: DENBUFYLLINE(57076-71-8)

Safety Data

• Hazardous Substances Data: 57076-71-8(Hazardous Substances Data)

Usage

Description

Denbufylline, a xanthine derivative and PDE4 inhibitor, has effects such as vasodilatation of cerebral vessels (Willette et al., 1997) and potent activation of the hypothalamic–pituitary–adrenal axis. PDE4 is one of the cyclic adenosine monophosphate (cAMP)–specic phosphodiesterases whose tissue distribution is important in pathologies related to the central nervous and immune systems. In experimental animals, denbufylline increases adrenocorticotropic hormone (ACTH), circulating corticosterone, luteinizing hormone, corticotrophin-releasing hormone, and cAMP content of the hypothalamic tissue, but is without effect on arginine vasopressin (Kumari et al., 1997). Treves and Korczyn (1999) studied patients with AD, mixed dementia, and VaD treated with denbufylline. No signicant differences were found in comparison with placebo for the treatment of AD or VaD, although patients who received denbufylline tended to improve their cognitive scores.

Chemical Properties

White Solid

Uses

Different sources of media describe the Uses of 57076-71-8 differently. You can refer to the following data:
1. A cell permeable xanthine derivatvie that acts as a selective inhibitor of phosphodiesterase IV (PDE IV). Possesses bronchodilatory properties. Displays negative inotropic effect by acting on a verapamil-sensitive site of the calcium channel in guinea pig ventricle apaillary muscle independently of its PDE inhibitory activity.
2. Bronchial spasmolysis agent

InChI:InChI=1/C16H24N4O3/c1-4-6-8-19-14-13(18(11-17-14)10-12(3)21)15(22)20(16(19)23)9-7-5-2/h11H,4-10H2,1-3H3

Relevant articles and documents

Combination preparation for use in dementia

The invention relates to a composition which is a pharmaceutical combination preparation comprising a compound which has an acetylcholinesterase-inhibitory action or exhibits muscarinergic action and a compound which increases the endogenous extracellular adenosine level, wherein the combination preparation is suitable for the treatment of dementia. The invention further relates to a process for the production of the combination preparation. The invention additionally relates to a process for treating patients in need of suitable therapy with the combination preparation.

Xanthine derivatives for the treatment of secondary nerve cell damage and functional disorders after cranio-cerebral traumas

The use of xanthine derivatives for the treatment of secondary nerve cell damage and functional disorders after cranio-cerebral traumas (CCT) The use of xanthine derivatives of the formula I STR1 and of their physiologically tolerable salts, in which R1 is oxoalkyl, hydroxyalkyl or alkyl, R2 is hydrogen or alkyl and R3 is hydrogen, alkyl, oxoalkyl or an alkyl having up to 6 carbon atoms, whose carbon chain is interrupted by an oxygen atom, for the production of pharmaceuticals for the treatment of disorders which can occur after cranio-cerebral traumas is described.